more

Innoviva (INVA)

(Delayed Data from NSDQ)

$20.12 USD

-0.06 (-0.30%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $20.08 -0.04 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Zacks News

Top Ranked Value Stocks to Buy for November 24th

by Zacks Equity Research Published on November 24,2020

Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 24th

Top Ranked Value Stocks to Buy for November 19th

by Zacks Equity Research Published on November 19,2020

Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 19th

Top Ranked Value Stocks to Buy for November 17th

by Zacks Equity Research Published on November 17,2020

Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 17th

Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma

by Zacks Equity Research Published on September 10,2020

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Innoviva (INVA) in Focus: Stock Moves 7% Higher

by Zacks Equity Research Published on September 03,2020

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

medical

Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on July 20,2020

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

biotechs

AbbVie (ABBV) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research Published on July 03,2020

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Has Innoviva (INVA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on June 23,2020

Is (INVA) Outperforming Other Medical Stocks This Year?

INVANegative Net Change

Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session

by Zacks Equity Research Published on June 23,2020

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

medical

AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on June 11,2020

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Innoviva (INVA) Stock Moves -0.77%: What You Should Know

by Zacks Equity Research Published on June 09,2020

Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.

INVANegative Net Change

Are Investors Undervaluing Innoviva (INVA) Right Now?

by Zacks Equity Research Published on June 08,2020

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

INVANegative Net Change

Innoviva (INVA) Gains But Lags Market: What You Should Know

by Zacks Equity Research Published on June 03,2020

Innoviva (INVA) closed the most recent trading day at $13.92, moving +0.43% from the previous trading session.

INVANegative Net Change

Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study

by Zacks Equity Research Published on June 03,2020

Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.

pharmaceuticals

AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding

by Zacks Equity Research Published on June 01,2020

The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.

pharmaceuticals

Innoviva (INVA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research Published on May 28,2020

Innoviva (INVA) closed at $14.36 in the latest trading session, marking a -1.64% move from the prior day.

INVANegative Net Change

Are Investors Undervaluing Innoviva (INVA) Right Now?

by Zacks Equity Research Published on May 21,2020

INVANegative Net Change

AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC

by Zacks Equity Research Published on May 19,2020

The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.